APA (7th ed.) Citation

Schwedt, T. J., Myers Oakes, T. M., Martinez, J. M., Vargas, B. B., Pandey, H. N., Pearlman, E. M., . . . Goadsby, P. J. (2023). Challenge-mig: A phase 4, randomized, double-blind, double-dummy study comparing the efficacy and safety of galcanezumab versus rimegepant for prevention of episodic migraine. Journal of the neurological sciences, 455, 121116. https://doi.org/10.1016/j.jns.2023.121116

Chicago Style (17th ed.) Citation

Schwedt, Todd J., et al. "Challenge-mig: A Phase 4, Randomized, Double-blind, Double-dummy Study Comparing the Efficacy and Safety of Galcanezumab Versus Rimegepant for Prevention of Episodic Migraine." Journal of the Neurological Sciences 455 (2023): 121116. https://doi.org/10.1016/j.jns.2023.121116.

MLA (9th ed.) Citation

Schwedt, Todd J., et al. "Challenge-mig: A Phase 4, Randomized, Double-blind, Double-dummy Study Comparing the Efficacy and Safety of Galcanezumab Versus Rimegepant for Prevention of Episodic Migraine." Journal of the Neurological Sciences, vol. 455, 2023, p. 121116, https://doi.org/10.1016/j.jns.2023.121116.